FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: IM Cannabis Corp. (the "Issuer").

Trading Symbol: IMCC

Number of Outstanding Listed Securities:

145,743,283 Common Shares, 9,730,258 Warrants

Date: April 7, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Corporate Developments:

• On March 9, 2020, Adjupharm GmbH, the Issuer's German distribution subsidiary ("Adjupharm"), entered into a supply, distribution and promotion agreement with a German distribution company. Pursuant to the supply agreement, Adjupharm will supply medical cannabis products to the German distributor in an amount to be determined based on a rolling forecast and a purchase order that the distributor shall submit to Adjupharm.

• On March 16, 2020, the Issuer held its annual general meeting of shareholders. Shareholders of the Issuer approved all items of business put forward, including fixing the number of directors at five; electing Oren Shuster, Marc Lustig, Steven Mintz, Rafael Gabay and Vivian Bercovici as directors; appointing Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global as auditors of the Issuer; and re-approving the Issuer's 10% rolling stock option plan.

• On March 25, 2020, Adjupharm entered into a supply, distribution and promotion agreement with a German distribution company. Pursuant to the supply agreement, Adjupharm will supply medical cannabis products to the German distributor in an amount to be determined based on a rolling forecast and a purchase order that the distributor shall submit to Adjupharm

• During March 2020, Adjupharm sold 3,000 grams of dried cannabis directly to pharmacies in Germany.

2. Provide a general overview and discussion of the activities of management.

Management of the Issuer remains focused on identifying new strategic investments and growth opportunities in Israel and Europe, including but not limited to securing German and European supply and distribution agreements and sales and supply agreement in the local Israeli market.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The current COVID-19 novel coronavirus ("COVID-19") situation in Germany has created high demand for medical equipment. Adjupharm has started to provide certain medical equipment to German pharmacies, doctors and patients. With almost 30 years of experience and network in the European Pharma Industry, Adjupharm has also applied its European pharmaceutical expertise to supplying disinfectants.

4. Describe and provide details of any products or services that  were discontinued. For resource companies, provide details of any  drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

• Adjupharm entered into two Supply Agreements with German distributors, as described in Item 1. The distributors are not Related Persons of the Issuer or Adjupharm.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

• On March 17, 2020, the Issuer terminated its agreement with MTM Medical Target Marketing Ltd., an Israel-based company that had provided strategy and marketing services to the Issuer in the Israeli market since July 2019.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable

8. Describe the acquisition of new customers or loss of customers.

Not Applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

On March 17, 2020, Adjupharm received the approval of the German authorities to import irradiated cannabis flowers to Germany. Adjupharm has registered 8 strains with different cannabinoid contents ranging from high THC and high CBD to balanced strains.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable

14. Provide details of any securities issued and options or warrants granted.

The issuer did not issue any common shares nor grant any options or warrants in March 2020.

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Not Applicable

16. Provide details of any changes in directors, officers or committee members.

At the Issuer's annual general meeting of shareholders on March 16, 2020, Rafael Gabay and Vivian Bercovici were elected to the Issuer's board of directors. Jesse Kaplan's term as a director of the Issuer concluded and he did not stand for re-election.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The current global uncertainty with respect to the spread of COVID-19, the rapidly evolving nature of the pandemic and local and international developments related thereto and its effect on the broader global economy and capital markets may impact the Issuer's business in the coming months.

The Issuer has taken proactive measures in the early stages of the COVID-19 pandemic to protect the health and safety of its employees, to continue delivering high quality medical cannabis to its patients and to maintain its strong balance sheet. The Issuer has postponed planned investments in innovation until global economic risks subside. The Issuer will focus on developing its brand in Germany by increasing volumes to medical patients in that market, adding supply and sales agreements in Israel, and reaching profitability in the near term.

While the precise impact of the COVID-19 outbreak on the Issuer remains unknown, rapid spread of COVID-19 and declaration of the outbreak as a global pandemic has resulted in travel advisories and restrictions, certain restrictions on business operations, social distancing precautions and restrictions on group gatherings which are having direct impacts on businesses in Canada, Israel and around the world and could result in additional precautionary measures that could impact the Issuer's business. The spread of COVID-19 may also have a material adverse effect on global economic activity and could result in volatility and disruption to global supply chains and the financial and capital markets, which could interrupt supplies and other services from third parties upon which the Issuer relies, decrease demand for products, cause staff shortages, reduced customer traffic, and increased government regulation, all of which may materially and negatively impact the business, financial condition and results of operations of the Issuer.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 7, 2020